Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age
| Autor: | Josef Priller, Steffen Wolfsgruber, Ruth Vukovich, Silka Dawn Freiesleben, Anja Schneider, Christoph Laske, Klaus Scheffler, Slawek Altenstein, Michael T. Heneka, Oliver Peters, Frank Jessen, Michael Wagner, Laura Dobisch, Frederic Brosseron, Klaus Fliessbach, Tommaso Ballarini, Annika Spottke, Julia Brunner, Ingo Frommann, Emrah Düzel, Alina Schröder, Eike Jakob Spruth, Jens Wiltfang, Franziska Maier, Robert Perneczky, Birgit Ertl-Wagner, Alfredo Ramirez, Ingo Kilimann, Nina Roy, Dietmar Hauser, Boris-Stephan Rauchmann, Daniel Janowitz, Matthias H. J. Munk, Debora Melo van Lent, Coraline D. Metzger, Peter Dechent, John-Dylan Haynes, Katharina Buerger, Stefan J. Teipel, Wenzel Glanz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Mediterranean diet business.industry Cognition medicine.disease Article 3. Good health 03 medical and health sciences 0302 clinical medicine Atrophy Internal medicine Brain size medicine Dementia ddc:610 030212 general & internal medicine Neurology (clinical) Effects of sleep deprivation on cognitive performance Alzheimer's disease Cognitive decline business 030217 neurology & neurosurgery |
| Zdroj: | Neurology 96(24), e2920-e2932 (2021). doi:10.1212/WNL.0000000000012067 Neurology |
| ISSN: | 1526-632X 0028-3878 |
| Popis: | ObjectiveTo determine whether following a Mediterranean-like diet (MeDi) relates to cognitive functions and in vivo biomarkers for Alzheimer disease (AD), we analyzed cross-sectional data from the German DZNE-Longitudinal Cognitive Impairment and Dementia Study.MethodThe sample (n = 512, mean age 69.5 ± 5.9 years) included 169 cognitively normal participants and individuals at higher AD risk (53 with relatives with AD, 209 with subjective cognitive decline, and 81 with mild cognitive impairment). We defined MeDi adherence according to the food frequency questionnaire. Brain volume outcomes were generated via voxel-based morphometry on T1-MRI, and cognitive performance was assessed with an extensive neuropsychological battery. AD-related biomarkers (β-amyloid42/40 [Aβ42/40] ratio, phosphorylated tau 181 [pTau181]) in CSF were assessed in n = 226 individuals. We analyzed the associations between MeDi and outcomes with linear regression models controlling for several covariates. In addition, we applied hypothesis-driven mediation and moderation analysis.ResultsHigher MeDi adherence related to larger mediotemporal gray matter volume (p < 0.05 family-wise error corrected), better memory (β ± SE = 0.03 ± 0.02; p = 0.038), and less amyloid (Aβ42/40 ratio, β ± SE = 0.003 ± 0.001; p = 0.008) and pTau181 (β ± SE = −1.96 ± 0.68; p = 0.004) pathology. Mediotemporal volume mediated the association between MeDi and memory (40% indirect mediation). Finally, MeDi favorably moderated the associations among Aβ42/40 ratio, pTau181, and mediotemporal atrophy. Results were consistent correcting for APOE-ε4 status.ConclusionOur findings corroborate the view of MeDi as a protective factor against memory decline and mediotemporal atrophy. They suggest that these associations might be explained by a decrease of amyloidosis and tau pathology. Longitudinal and dietary intervention studies should further examine this conjecture and its treatment implications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|